Close

Add to pipeline

Save Close
You are viewing a limited version of this profile. To access i3's full capabilities.
Ginkgo Bioworks
Save
Company logo (jpg or png)
Parent company
Edit alternate names

Short description

Engineer of biological organisms for applications in the energy, medicine and food sectors

Founded in 2008
Founded in

Company type Public Public (DNA)
Company type

Industry Group materials & chemicals

Sector biotechnology

TRL Range 9
TRL 1 Basic research
TRL 2 Technology formulation
TRL 3 Applied research
TRL 4 Small scale prototype
TRL 5 Large scale prototype
TRL 6 Prototype system
TRL 7 Demonstration system
TRL 8 First of a kind commercial system
TRL 9 Full commercial application
TRL Range

Ticker

Headquarters Boston, MA Boston, United States
Address
City
State
Zip
Country

Parent Companies

Website

Updated by Jonathan Koch at on 07/28/2017

Traction
  • 1 M&A items
tags
Similar companies
Customers
Save
Add Customer
Date Company
07/19/2023

Defense Advanced Research Projects Agency (DARPA) Defense Advanced Research Projects Agency (DARPA)

Ginkgo Bioworks awarded an $18M contract to develop cell-free synthesis for medicines.

Confirmed by Defense Advanced Research Projects Agency (DARPA)
Delete
Partnerships
Save
Add Partnership
Date Partner Type
07/16/2024
Syngenta Group Syngenta Group
Partnership with Syngenta (Crop Protection) to develop and optimize a microbial strain from the Syngenta Biologicals pipeline.
View source    
Confirmed by Syngenta Group
Development Partner
Delete
Investment Rounds
Save

IPO INFORMATION

Date

09/17/2021

IPO status

Listed

IPO Type

SPAC

Amount

$1.7B

Initial shares

Ticker symbol

DNA

Exchange listed

NASDAQ

Prospectus URL

Prospectus

Source URL

Source

Description

Ginkgo Bioworks plans to go public through via merger with SPAC, Soaring Eagle. The deal will generate $2.5 billion in gross cash processed including $1.7 billion from Soaring Eagle and $775 million from Baillie Gifford, Putnam Investments and accounts advised by ARK Investment Management. The deal gives Ginkgo a pre-money equity valuation of $15 billion.

Cancel Save
Add Investment
Date Investors Type Amount
09/17/2021 Baillie Gifford Baillie Gifford , Putnam Investments Putnam Investments , Ark Invest Ark Invest (3)
Post-money valuation of
PIPE $775,000,000
Delete
Click to add IPO information
Products
Save
Add Product
Product image Name Product status Revenue model Cost metrics
You are viewing a limited version of this profile. To access i3's full capabilities.
Back to top

Preload svg text font